Key Takeaways
- Oklo’s Q1 net deficit reached $33.1 million ($0.19 per share), significantly exceeding last year’s $9.8 million loss, while revenue remained at zero.
- The company received Nuclear Regulatory Commission approval for Aurora powerhouse’s Principal Design Criteria last week.
- Jacob DeWitte, CEO, reaffirmed plans to launch commercial operations no later than 2028.
- The company closed Q1 holding $1.59 billion in cash plus $614.5 million in marketable debt securities, accounting for approximately 82% of total assets.
- Following Q1 earnings, H.C. Wainwright maintained its Buy recommendation with a $90 price objective.
Shares of Oklo edged 0.6% higher during Wednesday’s premarket session following the nuclear technology firm’s quarterly earnings release and a significant regulatory achievement — despite deepening financial losses.
The firm reported a Q1 net deficit of $33.1 million, translating to $0.19 per share. This represents a substantial increase from the prior year’s $9.8 million loss, or $0.07 per share. Wall Street analysts had projected a $0.20 per share loss, meaning actual results narrowly beat consensus.
Oklo currently generates zero revenue. The company remains in its development phase, making conventional financial analysis difficult.
Capital expenditures on infrastructure and equipment totaled $32.8 million during the quarter — surpassing the $29.8 million analyst consensus. Operating costs reached $51.5 million, representing approximately a 10% decline from the previous quarter’s $57.1 million.
At quarter’s end, Oklo held $1.59 billion in cash reserves alongside $614.5 million in marketable debt securities. Combined, these assets comprise roughly 82% of the company’s total asset base.
The stock had declined 5.8% in the prior session before recovering in Wednesday’s premarket trading.
Aurora Reactor Secures Critical NRC Design Approval
The major regulatory development: the Nuclear Regulatory Commission granted approval for the Principal Design Criteria governing Oklo’s Aurora powerhouse facility at Idaho National Laboratory last week.
This approval establishes the fundamental safety and operational framework for the facility. While representing a significant milestone in the licensing pathway, complete commercial authorization remains outstanding.
CEO Jacob DeWitte has repeatedly stated to Barron’s that the company expects commercial operations to commence by 2028 or sooner.
Company Develops Multiple Revenue Streams
As Aurora progresses through regulatory channels, Oklo is pursuing alternative revenue opportunities.
Its subsidiary, Atomic Alchemy, obtained licensing approval earlier this year to commence commercial sales from its radiochemistry facility in Idaho. On Tuesday, Oklo disclosed that its inaugural isotope customer was “pending.”
The firm has also cultivated strategic partnerships with industry leaders. Last month, Oklo leveraged Nvidia’s AI infrastructure to enhance nuclear fuel modeling capabilities in collaboration with Los Alamos National Laboratory.
Meta Platforms ranks among Oklo’s established customers, bolstering the company’s standing with the investment community.
Since its public debut in May 2024, Oklo has traded primarily on future potential. The stock soared 238% throughout 2025 while the S&P 500 advanced 16%. Performance in 2026 has been more subdued — Oklo is up just 2.6% year-to-date compared to the S&P 500’s 8.1% gain.
The company currently commands a $12.81 billion market capitalization despite zero revenue generation — a valuation multiple that certain analysts consider elevated.
H.C. Wainwright reaffirmed its Buy rating and $90 price target on shares following the Q1 report.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
